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Zusammenfassung
Die Operation des Mammakarzinoms ist nach wie vor 
ein zentraler Therapieansatz. Heutzutage variieren Her-
angehensweisen der Resektion und Rekonstruktion je 
nach Tumor und Patientin erheblich. Diese Literaturzu-
sammenstellung stellt den aktuellen Wissensstand dar 
und diskutiert aufkommende Fragen, wie ausgedehnt die 
operative Therapie des Mammakarzinoms in verschiede-
nen klinischen Situationen sein sollte. Die Brusterhal-
tung ist beim frühen Mammakarzinom heute die Me-
thode der Wahl. Die Diskussion über Resektionsgrenzen 
wird nach wie vor kontrovers geführt, da verschiedene 
Studien widersprüchliche Ergebnisse zeigen. Die modifi-
ziert radikale Mastektomie ist der Standard bei der Be-
handlung des fortgeschrittenen Mammakarzinoms, 
wobei es hier sehr vielversprechende Ansätze der weite-
ren Reduzierung der Radikalität (Haut-, Areolen- und 
Nippelerhalt) gibt. Die Entfernung des Wächterlymph-
knotens kommt beim klinisch nodal negativen, invasiven 
Mammakarzinom heute in vielen Situationen zum Ein-
satz, wohingegen die Bedeutung der axillären Lympho-
nodektomie durch eine Reihe von ähnlichen Studien-
ergebnissen infrage gestellt wird. Obwohl verschiedene 
Studienergebnisse den Schluss nahelegen, bei sehr jun-
gen oder älteren Patientinnen individualisierte Konzepte 
zu verfolgen, bleibt es bisher bei Einzelfallentscheidun-
gen. Für BRCA-Mutationsträgerinnen und Patientinnen 
aus Hochrisikofamilien gibt es bislang keine besonderen 
operativen Empfehlungen.
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Summary
Surgery is still a main therapeutic option in breast 
cancer treatment. Nowadays, methods of resection and 
reconstruction vary according to different tumors and 
patients. This review presents and discusses standards 
of care and arising questions on how radical primary 
breast cancer surgery should be according to different 
clinical situations. In most early breast cancer patients, 
breast conservation is the method of choice. The discus-
sion on resection margins is still controversial as differ-
ent studies show conflicting results. Modified radical 
mastectomy is the standard in locally advanced breast 
cancer patients, although there are different promising 
approaches to spare skin or even the nipple-areola com-
plex. A sentinel node biopsy is the standard of care in 
clinically node-negative invasive breast cancer patients, 
whereas the significance of axillary lymphonodectomy 
seems to be questioned through a number of different 
findings. Although there are interesting findings to mod-
ify surgical approaches in very young or elderly breast 
cancer patients, it will always be an individualized ap-
proach if we do not adhere to current guidelines. Up to 
date, there are no special surgical procedures in BRCA 
mutation carriers or patients of high-risk families.
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Introduction
Breast cancer surgery is still a main therapeutic option in 
breast cancer treatment. Meanwhile, methods of resection 
and reconstruction vary according to different tumors and 
 patients. The goals of breast cancer surgery in combination 
with all other treatment efforts remain the same: amelioration 
of (disease-free) survival and quality of life. In line with 
 efforts to individualize systemic treatment, one even might 
discuss individual surgical approaches in specific situations. 
Do we need to perform or especially recommend to the pa-
tient the same surgical procedures regardless of age, medical 
history, family history, or tumor biology? Surgeons and pa-
tients might be interested in individualized surgical concepts.
This review will present and discuss standards of care 
and arising questions on how radical primary breast cancer 
surgery should be according to different clinical/patient 
situations.
Review of the Literature and Discussion
Early Breast Cancer
During the last century, breast cancer surgery has become less 
radical, starting with radical mastectomy [1] through modified 
radical mastectomy (MRM) to breast-conserving surgery 
(BCS) [2]. BCS with subsequent radiotherapy has proven to 
be equivalent to MRM alone with respect to survival [3, 4]. 
Since then, we may therefore conclude that BCS is the stand-
ard of care for patients with early breast cancer – in cases 
where it is technically feasible.
The aim of tumor-free resection margins (R0) has to be 
achieved [5, 6] because margin status is an important risk fac-
tor for local recurrence [7–10]. The optimal margin width is 
unclear up to now [7, 11, 12]. With respect to local recur-
rences, margins > 1 mm seem not necessarily to be more se-
cure than margins of 1 mm in invasive tumors [13–16]. Even 
clear margins do not guarantee complete excision, because 
positive reexcisions are even found in 21% of cases with ini-
tially negative margins [17]. In invasive cancers with extensive 
intraductal component (EIC), there are also studies proposing 
a safety distance of ≥ 5 mm [18]. On the other hand, we may 
adapt these aims according to topographic circumstances; e.g., 
when performing segmental resection up to the pectoralis fas-
cia, margins may be less in direction to the pectoralis fascia 
and in relation to neighboring skin [19]. With respect to resec-
tion margins in ductal carcinoma in situ (DCIS) only cases, 
there is a consensus that 2 mm should be achieved [19, 20] if a 
radiation therapy will be applied. A recent meta-analysis even 
favors more radical resection margins [21] on the basis of less 
long-term local recurrences, even in cases with radiation ther-
apy. In summary, the current guidelines propose a margin 
width of 1 mm in invasive cancers (regardless of an accompa-
nying in situ component) and 2 mm in DCIS only cancers [22].
Locally Advanced Breast Cancer
In locally advanced breast cancer – meaning large tumors 
 (absolute and relative to breast size), tumors infiltrating the 
pectoralis muscle or even the thoracic wall (intercostal mus-
cles), and skin involvement – one may consider more radical 
approaches. Standard of care is the MRM [23, 24]. There are 
no randomized controlled trials comparing MRM with skin-
sparing or even nipple-sparing approaches. Nevertheless, 
these techniques may be applied in selected situations and will 
probably not impair the oncological security [25]. It is difficult 
to properly define these selected situations because different 
studies reported on different surgical techniques (‘subcutane-
ous’ mastectomy with more subcutaneous tissue left behind 
the skin, skin-sparing or even nipple-sparing with or without 
intraoperative radiation, etc.). A rational approach might be 
to at least adhere to minimal resection margins as stated 
above (1 mm invasive, 2 mm DCIS).
Primary systemic treatment should be considered in locally 
advanced breast cancer. Even in these situations, complete 
tumor resection (i.e. tumor-free resection margins) is neces-
sary. In the majority of cases, mastectomy is needed. For ap-
propriately selected patients whose tumors show adequate 
downstaging after primary chemotherapy, breast preservation 
appears to be feasible and oncologically secure [26–30].
There is little information on inflammatory breast cancer 
(IBC) alone. It is defined as clinical signs of affected skin of 
> 1/3 of the breast involved (previous definition > 2/3 of the 
breast) [31]. Most retrospective analyses focus on T4 carcino-
mas without separating T4d cancers. IBC might be a distinct 
biological entity. Prospective randomized trials for the diag-
nosis and treatment of patients suffering from IBC are still 
missing.
Management of Axillary Lymph Nodes
One aspect of the surgical approach in patients with invasive 
breast cancer is determination of the histological lymph node 
status (pN). Nowadays, this is mainly reached by removing 
the sentinel node(s) [32–34]. In invasive breast cancer, senti-
nel lymph node biopsy (SNB) is the standard of care in pa-
tients without clinical or imaging signs of nodal involvement 
[35, 36]. SNB is equal to dissection of the whole axilla con-
cerning all oncological outcome measures (beginning with 
local control to overall survival (OS)), but morbidity is re-
duced significantly by performance of SNB [34, 37–42]. Con-
traindications are clinical suspicion of advanced lymph node 
involvement and positive lymph nodes, as well as after neo-
adjuvant chemotherapy, particularly if lymph nodes are suspi-
cious before chemotherapy [32, 33]. In case of neoadjuvant 
chemotherapy, the results of the SENTINA trial will perhaps 
change the clinical practice [43]. SNB can also be performed 
to reliably predict the nodal status in multicentric carcinomas, 
shown by functional studies of the patterns of lymph drainage 
and initial clinical data; however, empirical evidence is limited 
[44–47].
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In cases of 1 or 2 metastases in sentinel lymph nodes, it is 
unclear if these patients will benefit from performing a sec-
ondary axillary lymphonodectomy – provided that BCS was 
performed, no suspicious lymph nodes were found pre- and 
intraoperatively and that tangential whole breast irradiation 
will be applied [48]. In the referred ACOSOG Z0011 trial, 
no subgroup was found to benefit from a secondary lympho-
nodectomy; however, one has to take into account the short 
follow-up period and the small patient groups.
In patients with clinical nodal involvement, surgical re-
moval of axillary lymph nodes is still indicated because the 
amount of positive nodes might be relevant for systemic and 
radiation therapy decisions. There might also be minimally 
better local control of complete axillary dissection compared 
with radiation alone. In some special cases, only radiotherapy 
may be performed, e.g., if there is no information needed for 
the decision on systemic therapy or if the patient is very old 
[49–51]. In patients with tumors with microinvasion or very 
old patients, one may consider giving up all axillary interven-
tion [49, 52, 53]. In case of distant metastasis, axillary staging 
is not reasonable.
An axillary dissection in DCIS patients should not be ap-
plied; even an SNB should only be performed in mastectomy 
procedures or tumor resection near the axilla. In these cases, 
a secondary sentinel node biopsy is not technically feasible 
[36, 54]. In cases in which tumor invasion is assumed, an SNB 
may be performed [55, 56] to avoid a secondary surgical 
procedure.
Breast Cancer in Young Patients
Young age (mostly defined as age at first diagnosis ≤ 35 years) 
seems to be an independent risk factor for local recurrence 
and even OS [8, 10, 16, 57–59], even if the latter (effect of age 
on breast cancer survival) is still a matter of controversy. 
When adjusting for all prognostic variables, age was not 
 significantly related to mortality from breast cancer with 
a hazard ratio (HR) of 0.8 (95% confidence interval (CI): 
0.3–2.0) for very young and 1.1 (95% CI: 0.8–1.4) for young 
patients compared to older women [60]. Nevertheless large-
scale genomic analyses propose that breast cancer in young 
women might be a unique biologic entity driven by unifying 
oncogenic signaling pathways and characterized by less hor-
mone sensitivity and higher HER2 expression [61]. Young 
breast cancer patients are more likely to experience ipsilateral 
breast tumor recurrence (IBTR) after BCS. This difference is 
seen mainly among women with HER2 subtype. Based on 
these findings, more aggressive efforts to achieve local and 
systemic control might be considered for young women with 
HER2-subtype breast cancer [62].
Breast Cancer in Elderly Patients
In aging societies, breast cancer in older patients is an impor-
tant topic. Recently, the International Society of Geriatric On-
cology (SIOG) and the European Society of Breast Cancer 
Specialists (EUSOMA) updated their recommendations on 
screening, primary endocrine therapy, surgery, radiotherapy, 
neoadjuvant and adjuvant systemic therapy, and metastatic 
breast cancer in elderly patients [63]. In different studies, age 
has been described as an independent risk factor for non-re-
ceipt of effective cancer therapies, even when comorbidity and 
risk of recurrence are taken into account. After adjustment for 
comorbidity score, race, marital status, educational status, 
clinical stage, and tumor characteristics, increasing  patient age 
was independently associated with decreased guideline con-
cordance for definitive surgery, adjuvant chemotherapy, and 
adjuvant hormonal therapy [64]. The findings of the NORA 
(National Oncological Research observatory on Adjuvant 
therapy in breast cancer) study that indicate that age is signifi-
cantly related to later diagnosis and different, less efficient 
patterns of treatment may help to change attitudes that cur-
rently exclude a significant proportion of breast cancer pa-
tients from secondary prevention policies, more active treat-
ment strategies, and clinical research trials based on age [65].
Information regarding treatment effectiveness in this age 
group and tools that allow physicians and patients to estimate 
the benefits versus the risks of therapies, taking into account 
age and comorbidity burden, are critically needed [66]. Treat-
ments need to be adapted to the patient’s health status, but 
should also offer the best chance of cure [67].
Nonetheless, some data suggest adapted approaches in 
 elderly breast cancer patients:
Some years ago a Cochrane review on the topic ‘surgery 
and endocrine therapy in older women’ was published. The 
published literature comparing surgery, with or without adju-
vant endocrine therapy, with endocrine therapy alone in older 
women with operable breast cancer was systematically re-
viewed. When surgery alone was compared to endocrine ther-
apy alone, there was no significant difference in OS (HR 0.98, 
95% CI 0.74–1.30, p = 0.9), but a significant difference was 
found in progression-free survival (PFS) (HR 0.55, 95% CI 
0.39–0.77, p = 0.0006). When surgery with adjuvant endocrine 
therapy was compared to endocrine therapy alone, there was 
no significant difference in OS (HR 0.86, 95% CI 0.73–1.00, 
p = 0.06), but a significant difference was found in PFS (HR 
0.65, 95% CI 0.53–0.81, p = 0.0001) for surgery plus endocrine 
therapy versus primary endocrine. Primary endocrine therapy 
with tamoxifen has been associated with inferior local disease 
control but non-inferior survival to surgery for breast cancer 
in older women [68].
With respect to older patients, the current data increasingly 
suggest that operation of the axilla could be avoided in cases 
of small tumors and a clinically negative axilla [69]. Martelli 
et al. [69] presented the update of a study including 671 pa-
tients ≥ 70 years (172 with axillary dissection and 499 patients 
without an operation of the axilla) at a median follow-up time 
interval of 15 years. There was no significant difference in 
mortality within this group in the case of pT1 cN0 disease 
(10.7% vs. 10.7%, p = 0.836). Another study concluded that 
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tumor-related factors. Unfortunately, there is still a gap be-
tween explorative, hypothesis-generating studies and confirm-
ative trials to justify or falsify these approaches. Well-de-
signed and -conducted surgical trials are necessary.
Conclusions
Breast cancer surgery is still a main therapeutic option in 
breast cancer treatment. Meanwhile, methods of resection 
and reconstruction vary according to different tumors and 
patients.
In most early breast cancer patients, breast conservation is 
the method of choice. The discussion on resection margins is 
still controversial and the results of many studies show con-
flicting results. MRM is the standard in locally advanced 
breast cancer patients, although there are different promising 
approaches to spare skin or even the areola, or even the 
whole nipple-areola complex. A sentinel node biopsy is the 
standard of care in clinically node-negative invasive breast 
cancer patients, whereas the significance of axillary lympho-
nodectomy seems to be questioned through a number of dif-
ferent findings. Although there are interesting findings to 
modify surgical approaches in very young or elderly breast 
cancer patients, it will always be an individualized approach if 
we do not adhere to current guidelines. Up to date, there are 
no special surgical procedures in BRCA mutation carriers or 
patients of high-risk families because the performed surgeries 
(mastectomy instead of breast conservation, contralateral 
prophylactic mastectomy, and bilateral salpingoovarectomy) 
improve local control but probably not OS.
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avoiding axillary clearance for women ≥ 60 years who have 
clinically node-negative disease and receive tamoxifen for 
 endocrine-responsive disease yields similar efficacy, with 
 better early quality of life [53].
Breast Cancer in BRCA Mutation Carriers or Family History 
of Breast Cancers
In about 5–10% of breast cancer patients, we assume a ge-
netic disposition; woman with germ-line mutations in BRCA1 
or BRCA2 have a lifetime risk of 50–80% of developing 
breast cancer, a 30–40% risk of cancer in the contralateral 
breast after breast cancer, and a 10–40% risk of developing 
ovarian carcinoma [70–74]. Up to date, there is no special 
thera peutical recommendation for these cases of obvious fam-
ily history; therapy therefore follows guidelines for sporadic 
breast cancer. Nevertheless, prophylactic mastectomy of the 
second breast can be considered to reduce the risk of second 
contralateral carcinoma, but there seems to be no benefit with 
respect to improved OS [74–76].
Also bilateral oophorectomy can be performed to reduce 
the risk of a second carcinoma of ovaries and breast, but there 
is also no evidence for advantage in terms of survival [72]. On 
the other hand, there is some evidence in women with stage I 
or II carcinoma of the breast that a survival advantage might 
be possible through the reduced incidence of ovarian carci-
noma after bilateral oophorectomy [77].
Incidence of metachronic ipsilateral breast cancer recur-
rence does not seem to be higher, so breast-conserving ther-
apy is an adequate procedure if the woman does not want 
mastectomy [73]. Some studies have shown a lowered inci-
dence and mortality of BRCA-associated cancers if prophy-
lactic bilateral mastectomy was done [75, 76], but probably 
without effects on OS [78].
‘Targeted’ Breast Cancer Surgery
As already implied above, there are some ideas to further in-
dividualize breast cancer surgery according to patient- and 
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